
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Myriad Genetics collaborates with GSK to improve access to HRD testing in 9 countries

June 11, 2024 | News

HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer



US-based Myriad Genetics, Inc., a leader in genetic testing and precision medicine, has announced a collaboration with British pharmaceutical firm GlaxoSmithKline (GSK) aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients.

A new sponsored testing programme leveraging Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad's MyChoice Tests) is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudia Arabia, Singapore, and United Arab Emirates.

HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer. Myriad's MyChoice Tests determine HRD status in women with ovarian cancer. Clinicians can order this test through their local pathology labs and samples are sent to Myriad Genetics.

This collaboration delivers on both companies' shared commitment to improve care for patients with advanced ovarian cancer by facilitating access to genetic testing and demonstrates a mutual dedication to meeting an unmet need for patients who otherwise may not have access to testing.

"Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalized ovarian cancer treatment decisions," said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics. "In the pursuit of advancing healthcare equity, Myriad is committed to extending the reach of our diagnostic solutions, like Myriad's MyChoice Tests into additional markets to support more targeted patient care based on their genomic profile."